Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

January 16, 2024

Primary Completion Date

February 24, 2025

Study Completion Date

February 24, 2025

Conditions
Recurrent Acute Rhinosinusitis
Interventions
DRUG

Nitric Oxide Releasing Solution

The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.

DEVICE

Nasal spray with isotonic saline

The Sponsor designed a dual-chamber nasal spray bottle for NORS administration. The bottle will be filled with normal saline before being provided to the participant.

Trial Locations (7)

V1Y 1Z9

Okanegan Clinical Trials, Kelowna

V6V 2L1

Richmond Clinical Trials (Okanagan Clinical Trials Satelite Site), Richmond

L4W 1V7

Cliantha Research, Mississauga

M1S 4T7

Clinical Research of Ontario, Scarborough Village

G7H 7Y8

Intermed Groupe Santé, Chicoutimi

G2J 0C4

Alpha Recherche Clinique LeBourneuf, Québec

G3K 2P8

Alpha Recherche Clinique Val-Belair, Québec

All Listed Sponsors
lead

Sanotize Research and Development corp.

INDUSTRY

NCT06264141 - Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis | Biotech Hunter | Biotech Hunter